ArticleScientific reports2025
HLA-I genotype landscape in lung cancer and its prognosis value in Chinese small cell lung cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The human leukocyte antigen class I (HLA-I) genotypes have been proven to have an impact on the oncogenic mutational landscape and immunotherapy outcomes in several cancers. However, the HLA-I genotype landscape and its implications for lung cancer remain largely unknown. In this study, whole blood samples from 400 Chinese lung cancer patients were subjected to DNA sequencing for the detection of HLA-I genotypes. RNA sequencing data from 32 SCLC primary tumors were analyzed for immune cell infiltration and activity. Additionally, we collected HLA-I genotype and transcriptome data from 445 LUAD and 430 LUSC patients from The Cancer Genome Atlas (TCGA) database for comparisons. The proportion of HLA supertypes was similar among lung cancer patients with different pathological types but different among patients of different races. Chinese SCLC patients with the B44 supertype had more potent cytolytic activity and increased expression of MHC-II genes, interferon-gamma (IFN-γ), and chemokine signature genes than Chinese patients with other supertypes. Moreover, increased expression levels of immune checkpoint molecules were observed in tumors from B44(+) patients. Most importantly, we analyzed the correlation between the HLA supertype and prognosis and found that the positive effect of the HLA-B44 supertype on PFS verifies the prognostic value of HLA-B44 in SCLC. In conclusion, this study is among the first to depict the landscape of HLA-I genotypes in lung cancer patients. Comprehensive analysis revealed the effect of the B44 supertype on the tumor immune microenvironment and survival outcome of Chinese SCLC patients, providing fresh insight for the treatment of SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.